Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Get Free Report) has received a consensus rating of “Buy” from the ten brokerages that are currently covering the firm, Marketbeat reports. Ten investment analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have covered the stock in the last year is $27.89.
Several brokerages have commented on CNTA. Oppenheimer began coverage on shares of Centessa Pharmaceuticals in a report on Thursday, May 8th. They issued an “outperform” rating and a $6.00 price objective for the company. Guggenheim reiterated a “buy” rating and set a $28.00 target price on shares of Centessa Pharmaceuticals in a report on Wednesday, March 26th. Morgan Stanley reiterated an “overweight” rating and set a $27.00 target price on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Needham & Company LLC began coverage on shares of Centessa Pharmaceuticals in a report on Wednesday, May 28th. They set a “buy” rating and a $35.00 target price for the company. Finally, Chardan Capital began coverage on shares of Centessa Pharmaceuticals in a report on Thursday, May 8th. They set a “buy” rating and a $30.00 target price for the company.
Check Out Our Latest Stock Analysis on Centessa Pharmaceuticals
Centessa Pharmaceuticals Stock Performance
Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.15. On average, analysts anticipate that Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year.
Insider Buying and Selling
In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 14,656 shares of the business’s stock in a transaction on Monday, April 21st. The shares were sold at an average price of $12.29, for a total transaction of $180,122.24. Following the completion of the sale, the chief executive officer now directly owns 261,361 shares in the company, valued at approximately $3,212,126.69. The trade was a 5.31% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Gregory M. Weinhoff sold 11,742 shares of the business’s stock in a transaction on Friday, April 25th. The shares were sold at an average price of $13.61, for a total transaction of $159,808.62. Following the sale, the insider now owns 122,279 shares of the company’s stock, valued at approximately $1,664,217.19. This represents a 8.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 152,398 shares of company stock worth $1,945,852 in the last three months. Insiders own 7.09% of the company’s stock.
Institutional Investors Weigh In On Centessa Pharmaceuticals
A number of hedge funds have recently added to or reduced their stakes in CNTA. GF Fund Management CO. LTD. purchased a new stake in shares of Centessa Pharmaceuticals in the 4th quarter worth $31,000. Caitong International Asset Management Co. Ltd increased its stake in shares of Centessa Pharmaceuticals by 15,209.5% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company’s stock worth $46,000 after purchasing an additional 3,194 shares in the last quarter. Osterweis Capital Management Inc. purchased a new stake in shares of Centessa Pharmaceuticals in the 1st quarter worth $47,000. Barclays PLC increased its stake in shares of Centessa Pharmaceuticals by 1,414.9% in the 4th quarter. Barclays PLC now owns 5,302 shares of the company’s stock worth $89,000 after purchasing an additional 4,952 shares in the last quarter. Finally, BNP Paribas Financial Markets purchased a new stake in shares of Centessa Pharmaceuticals in the 4th quarter worth $162,000. 82.01% of the stock is currently owned by hedge funds and other institutional investors.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.
Further Reading
- Five stocks we like better than Centessa Pharmaceuticals
- What is Short Interest? How to Use It
- Microsoft Stock Holds Steady as AI Drives Workforce Shift
- Investing in Commodities: What Are They? How to Invest in Them
- D-Wave Goes International With South Korea Partnership
- Earnings Per Share Calculator: How to Calculate EPS
- Payment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?
Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.